KODIAK SCIENCES INC

Discover how Kodiak Sciences, a Nasdaq-listed biotech, is advancing retinal disease therapies, its market dynamics, and why investors should watch its clinical-stage journey.

Kodiak Sciences’ Zenkuda shows 62.5% vision improvement in Phase 3, cutting sight‑threatening risk by 85% and spurring a 68.6% stock surge.

Kodiak Sciences, a biopharmaceutical company focused on developing treatments for retinal diseases, faces significant financial and market challenges, raising concerns about its ability to deliver on its promises and achieve commercial success.